20/20 BioLabs, Inc. (NASDAQ: AIDX) expects its second quarter MCED revenue to reach a record high, increasing at least 30% compared to the prior-year quarter. The company projects this growth based on preliminary data, which has not yet been reviewed by auditors, for the three months ended June 30, 2026. This financial milestone accompanies the company's strategic push to position its OneTest™ for Cancer within the emerging Medicare reimbursement landscape for multi-cancer early detection (MCED) tests.

The company highlighted a new statutory pathway created by Congress that allows for Medicare reimbursement of FDA-authorized MCED blood tests starting in 2028. To access this coverage, OneTest™ requires both FDA authorization and a determination of clinical appropriateness by the Centers for Medicare & Medicaid Services (CMS). 20/20 BioLabs emphasized that neither authorization nor coverage has been secured, and there is no assurance these milestones will be achieved.

Strategic Differentiation and Evidence

20/20 BioLabs differentiates OneTest™ from circulating tumor DNA (ctDNA) approaches by utilizing a panel of protein tumor markers and inflammation-associated biomarkers. The technology employs machine learning and serial testing to monitor biomarker trajectories over time, rather than relying on a single snapshot. The company believes this method supports earlier detection and improved specificity through trend analysis, facilitated by at-home capillary blood collection.

The company is pursuing a totality-of-evidence strategy to support future regulatory and reimbursement engagements. This includes analytical validity, clinical validity, published studies, and real-world evidence. A key component of this strategy involves screening high-risk populations, with more than 35,000 American firefighters expected to be tested by the end of 2026.

Webinar Key Points

The inaugural investor webinar covered several strategic and operational areas:

• Regulatory Pathway: Medicare reimbursement for FDA-authorized MCED tests begins in 2028, subject to CMS clinical appropriateness criteria.
• Product Differentiation: OneTest™ utilizes serial biomarker tracking, protein tumor markers, and at-home collection to offer affordability and practicality.
• Clinical Context: The presentation reviewed expert concerns regarding the clinical utility of ctDNA-only approaches for broad population screening.
• M&A Strategy: The company plans to target acquisitions of companies with overlapping customer bases in health, wellness, and nutrition.

Jonathan Cohen, Chief Executive Officer of 20/20 BioLabs, stated that the strategy combines an affordable protein biomarker test with AI-enabled longitudinal analysis. He noted that while substantial work remains, the approach offers a differentiated path toward making multi-cancer early detection more accessible to Medicare beneficiaries.

The company also presented its OneTest™ for Longevity platform, which integrates inflammatory biomarkers and dietary assessment tools. This platform aligns with federal initiatives focused on nutrition and chronic disease prevention. The presentation included modeled sensitivity and specificity estimates, which the company clarified are hypothetical illustrations based on assumptions and not guarantees of future performance.

20/20 BioLabs announced the launch of a recurring monthly investor webinar series designed to enhance transparency and strengthen shareholder communication. The inaugural webinar is scheduled for Wednesday, July 1, 2026, at 12:00 p.m. ET, with subsequent sessions planned for the first Wednesday of each month. The series aims to provide investors with direct access to management and a comprehensive view of the company's progress.

Webinar Details

The monthly webinars will run approximately 45 minutes, offering consistent updates on the company's developments. Below are the details for the inaugural session:

Management Commentary

Jonathan Cohen, Chief Executive Officer of 20/20 BioLabs, emphasized the importance of regular engagement with shareholders. "We believe our shareholders deserve regular access to management and a deeper understanding of our strategy, progress, and long-term vision," Cohen stated. "This webinar series is designed to provide investors with a direct line of communication to the company, increase transparency around our business, and create an ongoing forum to discuss the opportunities we see ahead."

Additional Offerings

Attendees of the webinar will receive a promotional discount code for a single OneTest, regardless of shareholder status. The company also noted that replays of the webinars will be available in the investor relations section of its website at https://2020biolabs.com .

About 20/20 BioLabs

20/20 BioLabs develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The company offers two families of lab tests under the OneTest brand: OneTest for Cancer, a multi-cancer early detection (MCED) blood test, and OneTest for Longevity, which measures inflammatory biomarkers. Tests are conducted in the company's College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, MD.